Barclays Maintains Equal-Weight on Revance Therapeutics, Lowers Price Target to $3

BenzingaDec 23, 2024 20:43 · Ratings

Analysts Offer Insights on Healthcare Companies: Revance Therapeutics (RVNC) and Neurocrine (NBIX)

TipRanksDec 23, 2024 09:20 · Ratings

Revance Therapeutics Ticks Higher as Holder Says Crown Deal Undervalues Company

Seeking AlphaDec 19, 2024 23:10

Key Deals for the Week: Patterson, Hershey & Mondelez, AIG & Nippon and More

Seeking AlphaDec 14, 2024 21:25

Shareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

BusinesswireDec 13, 2024 00:30

Revance Therapeutics Board Recommends Stockholders Tender Shares to Crown Laboratories

MT NewswiresDec 12, 2024 23:55